9.08
-0.33 (-3.46%)
| Previous Close | 9.40 |
| Open | 9.20 |
| Volume | 46,609 |
| Avg. Volume (3M) | 141,052 |
| Market Cap | 6,352,500 |
| Price / Sales | 0.130 |
| Price / Book | 1.03 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -8,185.71% |
| Diluted EPS (TTM) | -1,320.00 |
| Quarterly Revenue Growth (YOY) | -63.70% |
| Total Debt/Equity (MRQ) | 1.13% |
| Current Ratio (MRQ) | 1.69 |
| Operating Cash Flow (TTM) | -11.58 M |
| Levered Free Cash Flow (TTM) | -6.17 M |
| Return on Assets (TTM) | -195.57% |
| Return on Equity (TTM) | -800.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Helius Medical Technologies, In | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 17.70% |
| % Held by Institutions | 6.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Grant Private Wealth Management Inc | 31 Mar 2025 | 62 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |